Autopsy report · NCT03776864
Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Cause of deathFunding or business
“Company providing drug terminated their oncology program”
Life of this trial
- Registered 9 months before it started.
- Ran for about 2 years before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 1 year 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Conditions
- Hodgkin's Lymphoma
- Interventions
- Pembrolizumab; Umbralisib
- Participants
- 6
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
“Cancer Therapy Evaluation Program's (CTEP's) termination of drug supply” - Panobinostat/Velcade in Multiple Myeloma
“This study was terminated because the drug company stopped making the study drug” - First-in-Human Study of TAK-280 in Participants With Solid Tumors
“Terminated due to limited anti-cancer activity” - Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
“The study was terminated due to company restructuring and changes in drug development priorities.” - A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
“Trial was terminated to allow sponsors to evaluate the future development of the drug program”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.